1 results about "Laquinimod" patented technology

This invention discloses the application of elamod in the preparation of drugs for treating neuromyelitis optica spectrum disorders (NMOSD). For the first time, in vivo animal experiments have demonstrated that elamod can significantly inhibit the production of pathogenic AQP4 antibodies in NMOSD model mice, improve motor function, retinal and optic nerve function, and reduce myelin damage. Unlike existing B-cell depletion monoclonal antibody therapies, elamod employs a "non-depletion" regulatory mode, inhibiting B-cell activation and antibody secretion without directly eliminating B cells, thus preserving some immune surveillance function and reducing the risk of long-term infection. Ailamod is an oral small molecule drug, included in the national medical insurance program, inexpensive, with no immunogenicity risk, and significantly better patient compliance than injectable monoclonal antibodies. This invention provides a novel, highly effective, and specific targeted drug for NMOSD, possessing significant clinical translational value.